Cargando…

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates representing four C. auris clades (South Asian n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovács, Renátó, Tóth, Zoltán, Locke, Jeffrey B., Forgács, Lajos, Kardos, Gábor, Nagy, Fruzsina, Borman, Andrew M., Majoros, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073555/ https://www.ncbi.nlm.nih.gov/pubmed/33923783 http://dx.doi.org/10.3390/microorganisms9040863

Ejemplares similares

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020)

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
por: Adnan, Awid, et al.
Publicado: (2023)

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
por: Tóth, Zoltán, et al.
Publicado: (2019)

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades
por: Papp, Zoltán, et al.
Publicado: (2021)

Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model
por: Forgács, Lajos, et al.
Publicado: (2020)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

In Vivo Efficacy of Amphotericin B against Four Candida auris Clades
por: Forgács, Lajos, et al.
Publicado: (2022)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
por: Caballero, Unai, et al.
Publicado: (2021)

1412. Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris
por: Dudiuk, Catiana, et al.
Publicado: (2018)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

In vitro and in vivo Effect of Exogenous Farnesol Exposure Against Candida auris
por: Nagy, Fruzsina, et al.
Publicado: (2020)

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms
por: Balla, Noémi, et al.
Publicado: (2022)

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis
por: Prépost, Eszter, et al.
Publicado: (2019)

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

Total transcriptome analysis of Candida auris planktonic cells exposed to tyrosol
por: Balla, Noémi, et al.
Publicado: (2023)

The Neosartorya fischeri Antifungal Protein 2 (NFAP2): A New Potential Weapon against Multidrug-Resistant Candida auris Biofilms
por: Kovács, Renátó, et al.
Publicado: (2021)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Growth characteristics of canine pathogenic viruses in MDCK cells cultured in RPMI 1640 medium without animal protein
por: Mochizuki, Masami
Publicado: (2006)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Aggravation of cold-induced injury in Vero-B4 cells by RPMI 1640 medium – Identification of the responsible medium components
por: Pless-Petig, Gesine, et al.
Publicado: (2012)

Increased Azithromycin Susceptibility of Multidrug-Resistant Gram-Negative Bacteria on RPMI-1640 Agar Assessed by Disk Diffusion Testing
por: Meerwein, Milton, et al.
Publicado: (2020)

Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report
por: Yamada, Shoko Merrit, et al.
Publicado: (2016)

Transcriptional Profiling of the Candida auris Response to Exogenous Farnesol Exposure
por: Jakab, Ágnes, et al.
Publicado: (2021)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

Transcriptional and translational landscape of Candida auris in response to caspofungin
por: Zamith-Miranda, Daniel, et al.
Publicado: (2021)

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience
por: Suh, Jinwoong, et al.
Publicado: (2019)

Successful treatment of C. auris shunt infection with intraventricular caspofungin
por: Singhal, Tanu, et al.
Publicado: (2018)

Caspofungin Affects Extracellular Vesicle Production and Cargo in Candida auris
por: Amatuzzi, Rafaela F., et al.
Publicado: (2022)

Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and Predicts In Vivo Outcomes in Galleria mellonella
por: Miller, Sarah, et al.
Publicado: (2022)

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
por: Kohno, S., et al.
Publicado: (2012)

Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study
por: Shalhoub, Sarah, et al.
Publicado: (2014)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris
por: Alanís-Ríos, Sergio A., et al.
Publicado: (2022)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates
por: de-la-Fuente, Iñigo, et al.
Publicado: (2023)

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
por: Hager, Christopher L, et al.
Publicado: (2018)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_okcpm6i1uoiam3i1ifea746f6m